why choose us

Clinical Trials Search

Showing 8,890 of 132,366 result(s)
Electronic Medical Record-Based Nudge to Reduce SLNB

Status: COMPLETED

Condition: Breast Cancer

Interventions: The nudge is a column in EPIC that flags patients coming to the clinic as a new visit with documented ER+ breast cancer.
The nudge flag can pop u

Date: 2023-08-17

MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Status: Completed

Condition: Arteriosclerosis

Interventions: MK-0616 20 mg tablet taken by mouth.

Date: 2023-08-17

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+;HER2- Advanced Breast Cancer

Status: Completed

Condition: Breast Cancer

Interventions: Patients will be treated with OP-1250 once daily on a 4 week (28 day) cycle

Date: 2023-08-17

Tele-video to Improve Daily Activity

Status: Completed

Condition: Physical Inactivity

Interventions: Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term acti

Date: 2023-08-17

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Status: NOT_YET_RECRUITING

Condition: Diffuse Large B Cell Lymphoma

Interventions: Allogeneic chimeric antigen receptor T cells (CAR-T) targeting both CD19 and CD20

Date: 2023-08-17

Aging Well Through Interactions and Scientific Education - Action Plan (AgeWISE-AP)

Status: NOT_YET_RECRUITING

Condition: Cognitive Aging

Interventions: 20-week program designed to provide education and individualized planning with a goal of improving brain health.

Date: 2023-08-17

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Status: Completed

Condition: Solid Tumors With HRAS Alterations

Interventions: Oral administration

Date: 2023-08-17

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Status: NOT_YET_RECRUITING

Condition: Chronic HIV Infection

Interventions: 100 mcg and 300 mcg

Date: 2023-08-17

JAK;STAT Inhibition in CNS Kohlmeier-Degos Disease

Status: Completed

Condition: Kohlmeier Degos Disease With Neurologic Involvement

Interventions: Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-24 weeks and 1 week of 5 mg BID before stopping ruxolitinib.

Date: 2023-08-17

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Status: Completed

Condition: Refractory Solid Tumors

Interventions: Given by vein (IV)

Date: 2023-08-17